Navigation Links
Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
Date:10/1/2013

the same price that was paid in the tender offer (eligible shares exclude those for which holders properly demanded appraisal under Delaware law and those held by Amgen or Onyx or their respective wholly owned subsidiaries). Following completion of the merger, Onyx shares will cease to be traded on the NASDAQ Global Market, which is expected to take effect later today.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward Looking Statements

This news release contains forward-looking statements that are based on Amgen's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described.  All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements about the planned completion of the tender offer and the merger, estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbit
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
2. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
3. Amgen To Participate At Citis 8th Annual Biotech Conference
4. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
5. Amgen to Highlight New Data at Upcoming ESC Congress 2013
6. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
7. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
8. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
9. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
10. Amgen Announces Webcast of 2013 Second Quarter Financial Results
11. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Bronstein, Gewirtz & Grossman, ... of the securities of PDL BioPharma, Inc. ("PDL BioPharma" ... Such investors are advised to contact Peretz Bronstein ... at info@bgandg.com or 212-697-6484. ... of its executives violated federal securities laws. ...
(Date:9/17/2014)... September 17, 2014 ... has shown positive data in a Phase 2a proof ... , Glenmark Pharmaceuticals today announced ... 1 (TRPA1) antagonist, GRC 17536 has shown positive data ... proof of concept study conducted on 138 patients in ...
(Date:9/17/2014)... 2014   MedeAnalytics today unveils Revenue ... complete visibility to a provider,s "mid-cycle" to optimize ... landscape. Powered by the industry,s leading big data ... point between patient access and the business office ... improve revenue capture, minimize audit risk and prepare ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... AUSTIN, Texas, March 4, 2011 Vermillion, Inc. (Nasdaq: ... Gail Page, Vermillion,s Chief Executive Officer, will be presenting at ... Ritz Carlton, Laguna Niguel in Dana Point, CA. ... 1:00 p.m. Pacific. The presentation will be web cast and ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix , today announced it plans to ... March 11, 2011 before the open of the financial ... call with the investment community at 8:00 a.m. PT ...
Cached Medicine Technology:Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA 2Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA 3Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11 2
(Date:9/17/2014)... Leading eco-friendly beauty brand , Lotus ... new vegan and gluten-free Sugar Cane Fruit Mask. Their ... results skincare testers were looking for. , “My ... mask that provided results, and I think I accomplished ... Fruit Mask combines Willow bark (Salix Alba extract), a ...
(Date:9/17/2014)... (HealthDay News) -- Scientists have developed a blood-cleansing device, ... the way the blood infection sepsis is treated. ... said their device works outside the body like a ... toxins out of patients, blood. "Even with the ... care units at least 30 percent of the time," ...
(Date:9/17/2014)... to reduce the need for invasive biopsies in patients ... , In a new study, researchers developed a math ... kidney inflammation to interstitial fibrosis, scarring in the ... is the only existing way to reach a definitive ... model could also be used to monitor the effectiveness ...
(Date:9/17/2014)... 17, 2014 CarePoint Health became the ... 150 CarePoint Health employees participated in the Ice Bucket ... Association. The event took place on September 9, ... CarePoint Health donated $100 to the ALS Association for ... total of approximately $15,000. The Ice Bucket Challenge was ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 ... made good on their pledge to cut calories in their ... together through the Healthy Weight Commitment Foundation, pledged to remove ... and 1.5 trillion by 2015. They,ve actually reduced far more: ... pledge and exceeded their pledge," said lead researcher Shu Wen ...
Breaking Medicine News(10 mins):Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:'Biospleen' Suggests New Way to Treat Blood Infection 2Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:CarePoint Health Accepts the Ice Bucket Challenge 2Health News:CarePoint Health Accepts the Ice Bucket Challenge 3Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3
... Minimal or Free and Best Option for Prevention;,Yet 5% Would ... Staying,Healthy., YONKERS, N.Y., Nov. 11 According to a ... to get the,flu vaccine this year, despite its being the ... long list of poor excuses,for not getting the vaccine, including ...
... First Large Scale Study Finds 73% Are From ... Consumers Union,called on hospitals today to take ... (C.-diff.) infections in light of a new report,showing ... estimates had,indicated. As the rate of hospital acquired ...
... French . , Montreal, November 11, 2008 ... that,s enabled them to reproduce complex cellular environments and ... a new study published in the journal Lab on ... Hospital Research Centre, McGill University and the Montreal Neurological ...
... is playing a key role in the largest, most ... Mental Health (NIMH) of adolescents and young adults at ... study joins the resources of Emory and seven other ... precise predictors for psychosis, and a better understanding of ...
... be an independent cause of excessive daytime sleepiness ... Researchers from Sweden performed polysomnography testing on 400 ... The apnea-hypopnea index (AHI) was calculated, and women ... very often were considered habitual snorers. Habitual snoring ...
... Proton Pump Inhibitors increase risk of major cardiovascular event by more ... for patients taking Plavix(R) Study may anticipate a role for genetic testing ... ... MHS ) today presented a study at the 2008 Scientific,Sessions of the ...
Cached Medicine News:Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 2Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 3Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 4Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 2Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 3Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 4Health News:New laser method reproduces art masterworks to protein patterns 2Health News:Pivotal Emory study focuses on teens at risk for psychosis 2Health News:Pivotal Emory study focuses on teens at risk for psychosis 3Health News:Journal CHEST: Nov. highlights 2Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 2Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 3Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 4
... Pulse Oximeter monitors SpO2, pulse ... is designed to provide fast, ... The device rejects spontaneous motion ... operator of excess artifacts and ...
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
Halogen-free immersion oil based on ester oil....
Immersion Oil, 150 cs...
Medicine Products: